 Maria Amaya
Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 13 | 2024 | 591 | 2.240 |
Why?
| | Neoplastic Stem Cells | 5 | 2025 | 377 | 0.990 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2025 | 1558 | 0.800 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.770 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 9 | 2025 | 215 | 0.770 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 46 | 0.760 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 130 | 0.700 |
Why?
| | Bendamustine Hydrochloride | 1 | 2020 | 11 | 0.680 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 190 | 0.680 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2024 | 51 | 0.640 |
Why?
| | Rituximab | 1 | 2020 | 162 | 0.630 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 105 | 0.620 |
Why?
| | Immunoconjugates | 1 | 2020 | 101 | 0.610 |
Why?
| | Azacitidine | 4 | 2023 | 139 | 0.580 |
Why?
| | Signal Transduction | 2 | 2022 | 4812 | 0.530 |
Why?
| | Sulfonamides | 8 | 2025 | 494 | 0.530 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 2 | 2013 | 25 | 0.500 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 384 | 0.480 |
Why?
| | Antibodies, Monoclonal | 2 | 2020 | 1354 | 0.470 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2025 | 112 | 0.420 |
Why?
| | gamma-Globins | 1 | 2013 | 1 | 0.420 |
Why?
| | Fetal Hemoglobin | 1 | 2013 | 6 | 0.420 |
Why?
| | Erythroid Cells | 1 | 2013 | 9 | 0.420 |
Why?
| | Gene Silencing | 2 | 2013 | 183 | 0.410 |
Why?
| | Autoantigens | 1 | 2013 | 416 | 0.340 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 573 | 0.330 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 379 | 0.330 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2025 | 744 | 0.310 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2041 | 0.300 |
Why?
| | Oxidative Phosphorylation | 2 | 2024 | 184 | 0.230 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 21 | 0.230 |
Why?
| | Leukemia, Myeloid, Chronic-Phase | 1 | 2024 | 1 | 0.220 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2508 | 0.210 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2024 | 99 | 0.210 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 165 | 0.210 |
Why?
| | Tumor Cells, Cultured | 4 | 2022 | 930 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 2 | 2025 | 875 | 0.190 |
Why?
| | Mutation | 2 | 2024 | 3682 | 0.180 |
Why?
| | Lipase | 1 | 2020 | 64 | 0.170 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 205 | 0.160 |
Why?
| | Recurrence | 2 | 2023 | 993 | 0.160 |
Why?
| | Repressor Proteins | 2 | 2013 | 399 | 0.150 |
Why?
| | Cell Survival | 1 | 2022 | 1073 | 0.150 |
Why?
| | Humans | 23 | 2025 | 128019 | 0.150 |
Why?
| | Mitochondria | 1 | 2024 | 847 | 0.150 |
Why?
| | Calcium | 1 | 2024 | 1182 | 0.150 |
Why?
| | Leukemia | 1 | 2020 | 228 | 0.150 |
Why?
| | Triazines | 1 | 2018 | 38 | 0.150 |
Why?
| | Prognosis | 3 | 2024 | 3766 | 0.150 |
Why?
| | Aminopyridines | 1 | 2018 | 95 | 0.140 |
Why?
| | Water Pollution, Chemical | 1 | 2016 | 5 | 0.130 |
Why?
| | Water Quality | 1 | 2016 | 31 | 0.130 |
Why?
| | Coal Mining | 1 | 2016 | 23 | 0.130 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1175 | 0.130 |
Why?
| | Groundwater | 1 | 2016 | 37 | 0.130 |
Why?
| | Blast Crisis | 2 | 2025 | 33 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2024 | 657 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2024 | 10110 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1356 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 955 | 0.110 |
Why?
| | Thromboplastin | 3 | 2002 | 69 | 0.100 |
Why?
| | Adult | 6 | 2024 | 35176 | 0.100 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2013 | 131 | 0.100 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 70 | 0.100 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2013 | 66 | 0.100 |
Why?
| | Liver | 1 | 2020 | 1826 | 0.100 |
Why?
| | Animals | 7 | 2025 | 34487 | 0.100 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 569 | 0.090 |
Why?
| | Melanoma | 3 | 2002 | 722 | 0.090 |
Why?
| | Mice | 5 | 2025 | 16574 | 0.090 |
Why?
| | Platelet Activation | 2 | 2008 | 89 | 0.090 |
Why?
| | Mice, Transgenic | 2 | 2013 | 2066 | 0.080 |
Why?
| | Carrier Proteins | 1 | 2013 | 730 | 0.080 |
Why?
| | Antigen-Antibody Complex | 1 | 2008 | 84 | 0.080 |
Why?
| | Receptors, IgG | 1 | 2008 | 74 | 0.080 |
Why?
| | Neoplasm Proteins | 2 | 2001 | 419 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3168 | 0.070 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 614 | 0.060 |
Why?
| | Models, Molecular | 1 | 2011 | 1482 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2013 | 4006 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2013 | 1896 | 0.060 |
Why?
| | Thrombosis | 1 | 2008 | 323 | 0.060 |
Why?
| | GTP Phosphohydrolases | 1 | 2024 | 83 | 0.060 |
Why?
| | Philadelphia Chromosome | 1 | 2024 | 18 | 0.060 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2024 | 64 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1421 | 0.050 |
Why?
| | Neuraminidase | 1 | 2003 | 24 | 0.050 |
Why?
| | Aged | 4 | 2024 | 21892 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 89 | 0.050 |
Why?
| | Trypanosoma cruzi | 1 | 2003 | 24 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2024 | 325 | 0.050 |
Why?
| | Young Adult | 3 | 2024 | 12281 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 119 | 0.050 |
Why?
| | CD40 Ligand | 1 | 2002 | 38 | 0.050 |
Why?
| | Tyrosine | 1 | 2003 | 218 | 0.050 |
Why?
| | Middle Aged | 4 | 2024 | 30812 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2024 | 238 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2023 | 165 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 88 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2024 | 14404 | 0.050 |
Why?
| | Glycoproteins | 1 | 2003 | 337 | 0.050 |
Why?
| | Blood Coagulation | 1 | 2002 | 226 | 0.040 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2001 | 60 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 73 | 0.040 |
Why?
| | Monocytes | 1 | 2002 | 546 | 0.040 |
Why?
| | Blood Platelets | 1 | 2002 | 376 | 0.040 |
Why?
| | Hemoglobins | 1 | 2001 | 336 | 0.040 |
Why?
| | Transcriptome | 1 | 2024 | 879 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2024 | 1105 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2001 | 226 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1681 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 442 | 0.030 |
Why?
| | Male | 4 | 2024 | 62757 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 620 | 0.030 |
Why?
| | Environmental Restoration and Remediation | 1 | 2016 | 10 | 0.030 |
Why?
| | Female | 4 | 2024 | 68016 | 0.030 |
Why?
| | Ohio | 1 | 2016 | 153 | 0.030 |
Why?
| | Stem Cells | 1 | 2020 | 577 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2598 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2001 | 1343 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2020 | 2337 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2011 | 157 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2020 | 3936 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 5268 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7029 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 509 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 441 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1169 | 0.020 |
Why?
| | Bevacizumab | 1 | 2008 | 129 | 0.020 |
Why?
| | Heparin | 1 | 2008 | 246 | 0.020 |
Why?
| | DNA Methylation | 1 | 2011 | 604 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 499 | 0.020 |
Why?
| | Adolescent | 1 | 2024 | 20158 | 0.020 |
Why?
| | Child | 1 | 2024 | 20636 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2008 | 754 | 0.010 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2003 | 167 | 0.010 |
Why?
| | Catalysis | 1 | 2003 | 305 | 0.010 |
Why?
| | Solubility | 1 | 2002 | 232 | 0.010 |
Why?
| | Factor VII | 1 | 2001 | 22 | 0.010 |
Why?
| | Chromatography, Affinity | 1 | 2001 | 83 | 0.010 |
Why?
| | Factor VIIa | 1 | 2001 | 38 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2003 | 796 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 55 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 2001 | 62 | 0.010 |
Why?
| | Dimerization | 1 | 2001 | 188 | 0.010 |
Why?
| | Factor Xa | 1 | 2001 | 32 | 0.010 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2001 | 41 | 0.010 |
Why?
| | Cell Communication | 1 | 2002 | 297 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2001 | 307 | 0.010 |
Why?
| | Kinetics | 1 | 2003 | 1617 | 0.010 |
Why?
| | Antibodies | 1 | 2001 | 392 | 0.010 |
Why?
| | Up-Regulation | 1 | 2002 | 822 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1286 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2001 | 1140 | 0.010 |
Why?
| | Protein Binding | 1 | 2001 | 2105 | 0.010 |
Why?
|
|
Amaya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|